8 results about "Bombesin" patented technology

The application belongs to the technical field of biological diagnosis, and relates to a subcellular organelle active targeting imaging probe and a preparation method thereof. The subcellular organelle active targeting imaging probe of the application is formed into nanoparticles (NPs) by coupling a fluorescent imaging probe with a special sequence of bombesin peptide and a derivative thereof; on one hand, the NPs can be surface-functionalized with lipophilic cations related to the NPs; on the other hand, the NPs can be passively targeted to tumor sites, and have high permeability and retention effect for solid tumors.

The invention relates to the technical field of avian proventriculitis, and provides a traditional Chinese medicine compound extract for preventing and treating avian proventriculitis, which is prepared from the following raw materials in parts by weight: 30 to 40 parts of radix astragali, 20 to 30 parts of radix codonopsis, 15 to 30 parts of rhizoma atractylodis macrocephalae, 15 to 20 parts of radix paeoniae alba, 12 to 20 parts of radix aucklandiae, 10 to 18 parts of rhizoma cyperi, 10 to 18 parts of fructus aurantii, 10 to 15 parts of herba taraxaci, 10 to 15 parts of pericarpium citri reticulatae, 8 to 15 parts of rhizoma zingiberis recens, 8 to 15 parts of medicated leaven, 8 to 15 parts of liquorice root and 1.0 to 3.0 parts of antibacterial peptide. The antibacterial peptide is bombesin or a derivative thereof, and the molecular weight of the antibacterial peptide is 1.8-3.5 kDa. Through the antibacterial peptide, the pathogenic bacterium killing rate is increased to 99.2%, and the drug resistance rate is 0; costunolide and antibacterial peptide are combined for use, the mucous membrane repairing speed is increased by 50%, the dosage is automatically adjusted by a drug delivery system according to the body weight, and excessive drug use is avoided; the pH adjusting module maintains the neutral environment of the liquid medicine and improves the stability of active ingredients.

The invention belongs to the technical field of biomedical polypeptides, particularly relates to a frombesin polypeptide compound or a pharmaceutically acceptable salt thereof, and further relates to application of the polypeptide or the pharmaceutically acceptable salt thereof in medicines for treating diseases related to GRPR. The polypeptide provided by the invention has the characteristics of high affinity, high plasma stability and long plasma half-life period.

There is provided a derivative compound of frombesin of the formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-psi-Xaa4-NH2), as well as a preparation method and application of the derivative compound of frombesin. RX comprises a radionuclide chelating agent or a prothetic group containing trifluoroborate. L is a linker. Xaa1 is D-Phe, Cpa (4-chlorophenyl alanine), D-Cpa, Tpi (2, 3, 4, 9-tetrahydro-1H-pyrido [3, 4b] indole-3-carboxylic acid), D-Tpi, Nal (naphthyl alanine), or D-Nal, or a pharmaceutically acceptable salt thereof. Xaa2 is Gly, N-methyl-Gly, or D-Ala, or a pharmaceutically acceptable salt thereof. And Xaa3 is Leu, Pro, D-Pro, or Phe. And Xaa4 is Pro, Phe, Tac (thiazolidine-4-formic acid), Nle (n-leucine) or 4-oxa-L-Pro (oxazolidine-4-formic acid). The symbol psi represents a reduced peptide bond between Xaa3 and Xaa4, where psi is CH2-N when Xaa4 is Pro, Tac or 4-oxa-L-Pro, or psi is CH2N (R) when Xaa4 is Phe or Nle, where R is H or a C1-C5 linear or branched alkyl group. Also provided are uses of such compounds as imaging agents or therapeutic agents.

The invention provides a composite nano-drug loaded with a mir-873 simulant and a mir-20a inhibitor as well as a preparation method and application of the composite nano-drug, and belongs to the technical field of drug preparation. According to the application disclosed by the invention, the fact that mir-873 and mir-20a can be used as composite targets of prostatic cancer is found on the basis of earlier-stage research, and a composite nano-drug loaded with a mir-873 simulant and a mir-20a inhibitor is prepared on the basis of the two targets of the mir-873 and the mir-20a; the composite nano-drug takes a mir-873 simulant and a mir-20a inhibitor as active substances, the active substances are coated with a composite nano-carrier, and the composite nano-carrier is obtained by compounding a cationic liposome, an endoplasmic reticulum membrane and bombesin polypeptide; the composite nano-drug is used for efficiently targeting prostatic cancer and inhibiting proliferation and metastasis of prostatic cancer, and the composite drug can be compounded with docetaxel to further efficiently inhibit prostatic cancer, so that the composite nano-drug has good practicability.

The present invention belongs to the field of biopharmaceutical polypeptide technology, specifically relating to a bombesin-like polypeptide compound or a pharmaceutically acceptable salt thereof, and further relates to the use of such a polypeptide or a pharmaceutically acceptable salt thereof in pharmaceuticals for treating GRPR-related conditions. The polypeptides of the present invention exhibit high affinity, high plasma stability, and a long plasma half-life.

To provide an improved radiotherapeutic agent for treating a disease associated with abnormal expression of a gastrin-releasing peptide receptor.SOLUTION: Provided is a bombesin-derived compound of formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX includes a radionuclide chelator or trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe or the like, and Xaa2 is Gly or the like. Xaa3 is Leu or the like, and Xaa4 is Pro or the like. A symbol ψ denotes reduced peptide bond between Xaa3 and Xaa4. In the case where Xaa4 is Pro or the like, ψ is CH2-N, or in the case where Xaa4 is Phe or Nle, ψ is CH2 N(R). R is H or a C1-C5 linear or branched alkyl. Use of the compound as a contrast medium or therapeutic agent is also provided.SELECTED DRAWING: None

The invention relates to the technical field of biological pharmacy, and particularly discloses application of protostemonine or pharmaceutical salt thereof in preparation of a medicine for preventing or treating acute pancreatitis. The establishment of an acute pancreatitis animal model induced by combination of rain frog element and LPS proves that protostemonine can significantly reduce the activity of model mouse serum amylase and lipase, alleviate pancreatic tissue pathological damage, inhibit the activity of pancreatic tissue myeloperoxidase (MPO) and mRNA expression of inflammatory factors IL-1beta, IL-6 and TNF-alpha, and inhibit pancreatic tissue myeloperoxidase (MPO). Therefore, local inflammation and tissue damage of the pancreas are effectively relieved. An in-vitro cell experiment further verifies the biological activity of the compound. The invention provides a new drug choice for clinical treatment of acute pancreatitis, and has a good development prospect. The medicine can be prepared into various dosage forms such as injections, tablets, capsules and the like, and can be combined with other anti-inflammatory medicines for use.